Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Liabilities and Shareholders Equity (2024 - 2025)

Kairos Pharma's Liabilities and Shareholders Equity history spans 2 years, with the latest figure at $6.5 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 13.38% year-over-year to $6.5 million; the TTM value through Dec 2025 reached $26.9 million, up 149.89%, while the annual FY2025 figure was $6.5 million, 13.38% up from the prior year.
  • Liabilities and Shareholders Equity reached $6.5 million in Q4 2025 per KAPA's latest filing, down from $6.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $7.9 million in Q1 2025 to a low of $5.0 million in Q3 2024.